For the first time, clinical interventions targeting biological aging have produced statistically significant human results — and the timeline for market availability has compressed in ways the longevity field has not yet fully communicated.
AI-designed drug candidates are entering clinical trials, quantum computers are outperforming classical systems on specific problems, and protein structure prediction has solved challenges that occupied structural biologists for decades. The transformation of the scientific method is underway.
After a decade of overhyped promises, microbiome science is producing reproducible clinical results in specific conditions. The interventions that work, and why they work, reveal a biology far stranger and more consequential than the popular science version.
Viruses don't want anything, of course. But thinking about viral evolution as if they did — as entities with strategies and trade-offs — turns out to be one of the most productive frameworks in modern biology.